OncoCyte Corporation (OCX)

NASDAQ: OCX · IEX Real-Time Price · USD
2.930
-0.010 (-0.34%)
Mar 28, 2024, 3:59 PM EDT - Market closed

Company Description

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.

The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.

OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OncoCyte Corporation
OncoCyte logo
Country United States
Founded 2009
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Joshua Riggs

Contact Details

Address:
15 Cushing
Irvine, California 92618
United States
Phone 949-409-7600
Website oncocyte.com

Stock Details

Ticker Symbol OCX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001642380
CUSIP Number 68235C107
ISIN Number US68235C2061
Employer ID 27-1041563
SIC Code 2835

Key Executives

Name Position
Joshua Riggs President, Chief Executive Officer and Director
James Liu Senior Director, Controller, Principal Accounting Officer and Interim Principal Financial Officer
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer
Peter Hong Vice President, General Counsel and Secretary
Yuh-Min Chiang Ph.D. Senior Vice President of Research & Development and Product Development
Sandra O'Donald Senior Vice President of Business Operations
Dr. Michael D. West Ph.D. Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc.
Sara Riordan Director of Medical Education

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 23, 2024 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Oct 10, 2023 8-K/A [Amend] Current report
Oct 5, 2023 8-K Current Report
Sep 20, 2023 8-K Current Report
Aug 28, 2023 8-K Current Report
Aug 10, 2023 10-Q Quarterly Report